ENTITY
Telix Pharmaceuticals

Telix Pharmaceuticals (TLX AU)

26
Analysis
Health CareAustralia
Telix Pharmaceuticals Limited operates as a biotechnology company. The Company develops and commercializes molecularly-targeted radiation therapy for the treatment of prostate, renal, and brain cancer. Telix Pharmaceuticals serves patients worldwide.
more
Refresh
20 Oct 2023 00:43

Telix Pharmaceuticals (TLX AU): Strong Q3 Result; Clinical Trial Setback Is a Temporary Dampener

​Telix reports positive operating cash flow for 3Q23, mainly driven by double-digit revenue growth from Illuccix in the U.S. However, shares pulled...

Logo
575 Views
Share
26 Aug 2023 17:45

Telix Pharmaceuticals (TLX AU): Strong 1H23 Result; Revenue Jumps 9x; 80% Reduction in Net Loss

US revenue of Telix’s prostate cancer imaging agent, Illuccix surged 11x to A$214M in 1H23, driven by the increasing market adoption of PSMA-PET...

Logo
424 Views
Share
03 Nov 2022 16:00

ASX Short Interest Weekly (Oct 28th): CSL, Woodside, Macquarie, Rio Tinto

We analyzed ASX short interest report for the past week and highlight short interest changes in CSL, Woodside, Macquarie, Rio Tinto, New Hope,...

Logo
144 Views
Share
13 Oct 2022 15:07

ASX Short Interest Weekly (Oct 7th): CBA, BHP, Westpac, Wesfarmers, CSL

We analyzed ASX short interest report for the past week and highlight short interest changes in  CBA, BHP, Westpac, Wesfarmers, CSL, South32,...

Logo
236 Views
Share
15 Aug 2022 15:25

Telix Pharmaceuticals (TLX AU): Illuccix Launched in US; Large Market Opportunity; Potential to Grow

Telix has launched Illuccix in the U.S., having a billion-dollar market opportunity. The company is progressing toward launch of the product in...

Logo
247 Views
Share
x